Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting.

被引：0

作者：

Mato, Anthony R.

Tang, Boxiong

Azmi, Soraya

Yang, Keri

Wallis, Nicola

Stern, Jennifer C.

Hedrick, Eric

Huang, Jane

Sharman, Jeff Porter

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] BeiGene Ltd, Emeryville, CA USA

[3] BeiGene USA Inc, San Mateo, CA USA

[4] BeiGene Ltd, Cambridge, MA USA

[5] Willamette Valley Canc Inst, Eugene, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e24044

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e24044

引用

页数：3

共 50 条

[31] ANALYSIS OF IMMUNE RELATED ADVERSE EVENTS IN NSCLC PATIENTS RECEIVING DURVALUMAB AFTER CHEMORADIOTHERAPY IN THE REAL-WORLD CLINICAL SETTING
Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Nakatani, Koichi
Mio, Tadashi
RESPIROLOGY, 2019, 24 : 50 - 50
[32] Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting
Ito, Tomoki
Hashimoto, Yoshinori
Tanaka, Yasuhiro
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Konishi, Akiko
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Hashimoto, Akiko
Kondo, Toshinori
Omura, Hiromi
Shinzato, Isaku
Tanaka, Takayuki
Nomura, Shosaku
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (02) : 116 - 123
[33] Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting
Ups, Katherine
Francesconi, Alessandra
Ryan, Elizabeth G.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 114 - 114
[34] First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Fujii, Yasutoshi
Kawaoka, Tomokazu
Shirane, Yuki
Miura, Ryoichi
Nakahara, Hikaru
Yamaoka, Kenji
Uchikawa, Shinsuke
Fujino, Hatsue
Ono, Atsushi
Murakami, Eisuke
Miki, Daiki
Hayes, Nelson Clair
Tsuge, Masataka
Nakamura, Yuko
Awai, Kazuo
Oka, Shiro
ONCOLOGY, 2024,
[35] Real-world treatment patterns and outcomes among patients with BRAF plus metastatic melanoma refractory to first-line immunotherapy
Truong, T. G.
Chandra, S.
Connolly, L.
Shah, R.
Byrne, C.
Tang, J.
Eroglu, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S673 - S673
[36] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Shadman, Mazyar
Srivastava, Bhavini P.
Salkar, Monika
Saifan, Chadi
Agatep, Barnabie C.
Jones, Barton
Ryan, Olga
Bacchus, Shaffee
Stephens, Deborah M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Overall survival and treatment patterns among real-world patients with metastatic urothelial carcinoma treated with first-line therapy
Simeone, Jason C.
Nordstrom, Beth L.
Patel, Ketan
Klein, Alyssa B.
Horne, Laura
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 102 - 102
[38] First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Basile, D.
Bergamo, F.
Ongaro, E.
Cinausero, M.
Conca, V.
Ambrosini, M.
Lucchetti, J.
Rosati, G.
Avallone, A.
Di Paolo, G.
Lai, E.
Lutrino, E. S.
Di Nardo, P.
Zurlo, I. V.
Cortese, C.
Carullo, M.
Leo, S.
Di Donato, S.
Pietrantonio, F.
Aprile, G.
ANNALS OF ONCOLOGY, 2024, 35 : S447 - S447
[39] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
Zhang, H.
Cun, F. S.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
[40] Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study
Kabadi, Shaum M.
Byfield, Stacey Dacosta
Le, Lisa
Olufade, Temitope
ANTICANCER RESEARCH, 2021, 41 (02) : 927 - 936

← 1 2 3 4 5 →